Global Pharmaceuticals, the generic division of Impax Laboratories, has begun shipment of authorized generic Zomig (zolmitriptan) tablets and orally disintegrating tablets, 2.5 mg and 5 mg, in the US, as part of a distribution, license, development and supply agreement with AstraZeneca UK Limited (AstraZeneca). Zomig is indicated for the treatment of migraine headaches in adults.

According to IMS Health data, US sales of Zomig tablets and orally disintegrating tablets were approximately $196 million in the 12 months ended April 2013.

Zomig and Zomig-ZMT are registered trademarks of the AstraZeneca group of companies.

Impax Laboratories, Inc. is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous system disorder branded products.